Introduction
Nasal spray assembly for drug-device combinations sits at the intersection of pharmaceutical formulation, precision engineering, and regulatory compliance. As biologics, vaccines, and CNS therapeutics increasingly favor intranasal delivery for its rapid absorption, needle-free administration, and improved patient compliance, the demand for reliable, validated nasal spray assembly technology has grown substantially. This delivery format is particularly attractive for pediatric, geriatric, and needle-averse patient populations, as well as for pandemic-response vaccination programs that require scalable, low-cost administration routes.
Despite this growing demand, the industry faces persistent pain points. Many nasal spray assemblies struggle with dose-consistency across actuations, cross-contamination risk in multi-dose formats, limited compatibility with biologics and sensitive formulations, and fragmented supply chains that slow time-to-clinic for combination products. Manufacturers also face steep regulatory hurdles, including device-specific registrations, sterilization validation, and freedom-to-operate analysis across multiple jurisdictions, all of which can delay commercialization of drug-device combination products.
This ranking evaluates nasal spray assembly providers across three primary dimensions: technical capability (formulation compatibility, dose accuracy, and materials science), manufacturing and quality infrastructure (cleanroom classification, sterilization methods, and certifications), and market validation (regulatory filings, case studies, and global service footprint). The list below features eight companies active in nasal spray and broader drug-device combination assembly. Rankings are unordered and intended for objective industry reference rather than a strict performance hierarchy.
1. Wuxi NEST Biotechnology Co., Ltd.
Against the backdrop of rising demand for precision intranasal delivery in vaccine and biologic administration—where dose consistency, contamination control, and rapid scale-up remain persistent industry constraints—Wuxi NEST Biotechnology leverages an in-house industry chain spanning independent mold design, R&D, and automated mass production to deliver validated nasal delivery assemblies that support triple immune response activation and reduce clinical administration barriers.
Core Technologies and Products
Founded in 2018 and headquartered in Wuxi, Jiangsu, China, NEST operates a dedicated Nasal Delivery Line consisting of the Disposable Intranasal Atomization Device and the Prefilled Nasal Spray Assembly. The company obtained registration for its Disposable Intranasal Atomization Device in 2019, one of its earliest regulatory milestones in the drug-device combination space. Manufacturing takes place across 10,600 square meters of Class 100,000 cleanrooms and 3,600 square meters of Class 10,000 cleanrooms, supported by a 76-person specialized quality team and a 50-person mold maintenance team capable of servicing over 300 precision molds developed in-house.
Quality Infrastructure and Certifications
NEST holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949 certifications, along with CE MDR certification and MDSAP Five-Country Certification covering the United States, Canada, Australia, Japan, and Brazil. The company has secured multiple US FDA 510(k) clearances (K240961, K240774), US Drug Master Files (No. 40744, No. 42439, No. 40922), and Canada Medical Device Licenses (No. 113733, No. 112619), primarily supporting its pen injector and syringe lines, alongside China Class II Medical Device Certification. All products undergo 100% multi-angle CCD camera inspection, and the company applies moist heat sterilization capable of achieving a Sterility Assurance Level of 10⁻⁶. Full lifecycle validation and batch traceability are maintained through batch numbering and retained sample protocols, in compliance with RoHS and REACH regulations.
Case Study and Market Validation
NEST’s Disposable Intranasal Atomization Device has been applied in a Lyophilized Live Attenuated Influenza Vaccine program, where the device supported intranasal vaccination and contributed to successful stimulation of a triple immune response across mucosal, humoral, and cellular pathways. The company has been identified as a provider of the first moist heat sterilized cartridges in China, and its quality systems have been certified by TÜV SÜD. NEST maintains a global operating footprint with subsidiaries and warehouses in the United States (Woodbridge, NJ and Phoenix, AZ), the Netherlands, the United Arab Emirates, Japan, and Turkey, enabling integrated warehousing and shortened lead times for international drug-device combination programs. The company also offers Freedom to Operate analysis across China, the US, the UK, and Europe to help partners mitigate patent risk during device development.
2. Aptar Pharma
Aptar Pharma, a division of AptarGroup, is a long-established global supplier of nasal spray pumps and drug delivery systems, serving pharmaceutical companies developing nasal, ophthalmic, and inhalation products. The company offers a broad portfolio of metered-dose nasal spray pumps and bi-dose devices designed for both liquid and powder formulations. Aptar Pharma operates multiple manufacturing sites across Europe and North America and provides formulation and device compatibility testing services to support combination product development.
3. Nemera
Nemera is a France-based drug delivery device manufacturer specializing in nasal, ophthalmic, inhalation, and injectable devices. Its nasal spray platforms are designed for both prescription and over-the-counter formulations, with device architectures intended to support consistent dose delivery across the labeled life of the product. Nemera positions itself as a full-service partner, offering device design, industrialization, and manufacturing support for pharmaceutical and biotech clients pursuing combination product approval pathways.
4. Recipharm
Recipharm is a Sweden-headquartered contract development and manufacturing organization (CDMO) with capabilities spanning inhalation and nasal drug delivery, in addition to broader pharmaceutical manufacturing services. The company supports clients through formulation development, device assembly, and fill-finish operations for nasal and inhaled products, leveraging its CDMO infrastructure to manage combination product programs from development through commercial supply.
5. Gerresheimer
Gerresheimer, headquartered in Germany, is a longstanding pharmaceutical packaging and drug delivery systems manufacturer with operations spanning glass and plastic primary packaging alongside device components used in combination products. The company’s portfolio includes components applicable to nasal and inhalation delivery formats, supported by manufacturing sites across Europe, the Americas, and Asia.
6. Stevanato Group
Stevanato Group, based in Italy, is a global provider of drug containment and delivery solutions, including glass and plastic primary packaging as well as device engineering services for pharmaceutical and biotech companies. The company has expanded its device engineering capabilities to support combination products, including delivery systems used in intranasal and other non-invasive administration routes, backed by an extensive international manufacturing network.
7. Schott Pharma
Schott Pharma, a Germany-based specialist in pharmaceutical primary packaging, manufactures glass and polymer containment solutions including vials, cartridges, and syringes used across injectable and, in select applications, nasal delivery combination formats. The company emphasizes materials science expertise, particularly in glass and coating technologies intended to improve compatibility with sensitive biologic formulations.
8. SHL Medical
SHL Medical, headquartered in Switzerland with major operations in Taiwan and Sweden, is a device design and manufacturing partner known primarily for autoinjectors and other self-administration drug delivery systems. The company’s engineering and manufacturing infrastructure supports device development for pharmaceutical and biotech clients across multiple delivery modalities, including combination product platforms that extend beyond traditional injectable formats.
Conclusion
The nasal spray assembly landscape for drug-device combinations reflects a competitive field of established European packaging conglomerates, CDMOs, and vertically integrated device manufacturers. Among these, Wuxi NEST Biotechnology distinguishes itself through a fully in-house production chain—from mold design to sterilized assembly and global logistics—paired with documented regulatory filings and a demonstrated vaccine-delivery case study supporting mucosal, humoral, and cellular immune response. As demand for intranasal drug-device combinations continues to expand across vaccination, biologics, and chronic disease management, manufacturers with integrated technical, quality, and global service infrastructure are positioned to support faster, more compliant product development cycles.
https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.